Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The luminal subtype of breast cancer has heterogeneous biological characteristics with respect to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and Ki-67. We analyzed luminal B breast cancer subcategorized by PR expression and identified clinically relevant prognostic factors. Methods: We collected the clinical and pathologic data of 247 breast cancer patients (stage 1-4) who were diagnosed with luminal B subtype, defined as ER- and/or PR-positive and/or HER2-positive and with a high Ki-67 proliferation index (>14%). We classified them into PR intact and PR low groups according to PR expression pattern. We also analyzed the clinical and pathological data of each group, including age at diagnosis, tumor size, node metastasis, breast and axillary operative method, margin involvement, tumor-node-metastasis (TNM) stage, histological grade, nuclear grade, number of tumors, and expression of ER, PR, Ki-67, and Bcl-2; evaluated recurrence or metastatic characteristics; and analyzed disease-free survival (DFS) and overall survival (OS) in both groups. Results: Among the 247 luminal B breast cancer patients (stage 1-4), 141 were classified into the PR intact group (57.1%) and 106 into the PR low group (42.9%). The PR low group was associated with age >50 years (p=0.001), low Bcl-2 expression (p<0.001), and high proportion of mastectomies (p<0.001). DFS and OS were significantly lower in the PR low group (p=0.025 and 0.024, respectively). Conclusion: This study showed that decreased in PR expression (PR low group) in luminal B breast cancer was related to poor prognosis compared to normal PR expression (PR intact group).
Abstract
Purpose: The luminal subtype of breast cancer has heterogeneous biological characteristics with respect to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and Ki-67. We analyzed luminal B breast cancer subcategorized by PR expression and identified clinically relevant prognostic factors. Methods: We collected the clinical and pathologic data of 247 breast cancer patients (stage 1-4) who were diagnosed with luminal B subtype, defined as ER- and/or PR-positive and/or HER2-positive and with a high Ki-67 proliferation index (>14%). We classified them into PR intact and PR low groups according to PR expression pattern. We also analyzed the clinical and pathological data of each group, including age at diagnosis, tumor size, node metastasis, breast and axillary operative method, margin involvement, tumor-node-metastasis (TNM) stage, histological grade, nuclear grade, number of tumors, and expression of ER, PR, Ki-67, and Bcl-2; evaluated recurrence or metastatic characteristics; and analyzed disease-free survival (DFS) and overall survival (OS) in both groups. Results: Among the 247 luminal B breast cancer patients (stage 1-4), 141 were classified into the PR intact group (57.1%) and 106 into the PR low group (42.9%). The PR low group was associated with age >50 years (p=0.001), low Bcl-2 expression (p<0.001), and high proportion of mastectomies (p<0.001). DFS and OS were significantly lower in the PR low group (p=0.025 and 0.024, respectively). Conclusion: This study showed that decreased in PR expression (PR low group) in luminal B breast cancer was related to poor prognosis compared to normal PR expression (PR intact group).
참고문헌 (26)
- Viale G, "Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer : predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group", J Clin Oncol, 26, pp.1404~1410 (2008)
- Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Oh DS, "Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers", J Clin Oncol, 24, pp.1656~1664 (2006)
- Ades F, "Luminal B breast cancer : molecular characterization, clinical management, and future perspectives", J Clin Oncol, 32, pp.2794~2803 (2014)
- Esserman LJ, "Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007", 150012, ACRIN 6657), 2009, pp.27(18_suppl), LBA515~
- de Ronde JJ, "Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response", Breast Cancer Res Treat, 119, pp.119~126 (2010)
- Bhargava R, "Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy : a single institutional experience with 359 cases", Cancer, 116, pp.1431~1439 (2010)
- Carey LA, "The triple negative paradox : primary tumor chemosensitivity of breast cancer subtypes", Clin Cancer Res, 13, pp.2329~2334 (2007)
- Han-Sung Kim, "Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer", Journal of Breast Cancer, 15(4), pp.401~406 (2012), 한국유방암학회[DOI]
- 박경미, "Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer", Journal of Breast Cancer, 14(4), pp.276~282 (2011), 한국유방암학회
- Hudis CA, "Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials : the STEEP system", J Clin Oncol, 25, pp.2127~2132 (2007)
- Tran B, "Luminal-B breast cancer and novel therapeutic targets", Breast Cancer Res, 13, pp.1~10 (2011)
- Li ZH, "Luminal B breast cancer : patterns of recurrence and clinical outcome", Oncotarget, 7, pp.65024~ (2016)
- Ignatiadis M, "A meta-analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal-like breast cancer", Cancer Res, 69(24_supple), pp.106~ (2009)
- Györffy B, "Meta-analysis of gene expression profiles related to relapse-free survival in 1, 079 breast cancer patients", Breast Cancer Res Treat, 118, pp.433~441 (2009)
- Harbeck N, "St. Gallen 2013 : brief preliminary summary of the consensus discussion", Breast care, 8, pp.102~109 (2013)
- Sørlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci, 98, pp.10869~10874 (2001)
- Cancello G, "Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse", Ann Oncol, 24, pp.661~668 (2013)
- Nishimukai A, "High Ki-67 Expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer", Clin Breast Cancer, 15, pp.204~211 (2015)
- Domagala W, "Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma : its relationship with vimentin and p53 protein", Clin Cancer Res, 2, pp.147~154 (1996)
- Trihia H, "Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker?", Cancer, 97, pp.1321~1331 (2003)
- de Azambuja E, "Ki-67 as prognostic marker in early breast cancer : a meta-analysis of published studies involving 12 155 patients", Br J Cancer, pp.1504~1513 (2007)
- Dawson SJ, "BCL2 in breast cancer : a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received", Br J Cancer, 103, pp.668~675 (2010)
- Cory S, "The Bcl-2 family : roles in cell survival and oncogenesis", Oncogene, 22, pp.8590~8607 (2003)
- Cui X, "Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy", J Clin Oncol, 23, pp.7721~7735 (2005)